Cethromycin, Advanced Life Sciences’ lead product candidate, is a novel
once-a-day antibiotic that recently demonstrated positive phase III
results for the treatment of community acquired pneumonia (CAP). Tested
in approximately 5,200 human subjects, cethromycin has shown higher in
vitro potency and a broader range of activity than macrolides against
Gram-positive bacteria associated with respiratory tract infections,
and, again in in vitro tests, it appears to be effective against
penicillin and macrolideresistant bacteria. Cethromycin has a mechanism
of action that may slow the onset of future bacterial resistance.
http://www.advancedlifesciences.com/product.php?id=1
Cethromycin is an antibiotic in the ketolide class.
The first ketolide antibiotic to be marketed, Ketek (telithromycin),
turned out to cause uncommon but severe side effects (irreversible liver
failure). A further investigation revealed that a key clinical trial of
Ketek had been conducted fraudulently. Following those revelations, the
FDA ordered the labeling of Ketek changed to permit its use only for
community-acquired pneumonia.
Advanced Life Sciences claims it's unlikely that Cethromycin will share
Ketek's problems.
--
Steven L.
Email: sdlit...@earthlinkNOSPAM.net
Remove the NOSPAM before replying to me.
|
